title: Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.
abstract: OBJECTIVE
  The article presents the rationale, clinical development, and current status of poly (ADP ribose) polymerase inhibitors (PARPis) as anticancer agents.
  
  
  RESULTS
  The recent approval of olaparib in heavily pretreated patients with advanced ovarian cancer carrying a BRCA1/2 mutation represents a significant therapeutic advance for patients with this difficult to treat disease. Though olaparib is the first agent in this class to be approved, multiple PARPis are in various stages of clinical development, including in combination with other treatment modalities such as radiation, antiangiogenic agents, and cytotoxic chemotherapies.
  
  
  CONCLUSIONS
  Clinical benefit has been observed with PARPis in patients with advanced BRCA1/2 mutant ovarian and breast cancers. Various PARPis, either as single agents or in combination, are being evaluated in the neoadjuvant, adjuvant, and metastatic settings.
authors.affiliation: aDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland bDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California, USA.
authors.forename: Geraldine
authors.initials: G
authors.lastname: OʼSullivan Coyne
authors.forename: Alice
authors.initials: A
authors.lastname: Chen
authors.forename: Shivaani
authors.initials: S
authors.lastname: Kummar
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004249:DNA Damage / Q000187:drug effects; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors